Back

Clinical characteristic of LVAD recipients required over and lower than median dosage of loop diuretic during 12 month following the implantation

13 May 2024 (15:00 - 16:00)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - treatment 6 Ventricular Assist Devices HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Sylwia Wisniowska-Smialek

Jagiellonian University Medical College, John Paul II Hospital, Krakow (Poland)

7 More presentations in this session

Presentation thumbnail
Identifying predictors of non-response to cardiac resynchronization therapy in heart failure patients
Doctor L. Pinheiro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Predictors of cardiac resynchronized therapy response and maximum allowable medical treatment period in dilated cardiomyopathy with left bundle branch block
Doctor M. Bak (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Cardiac resynchronisation therapy's response in patients with atrial fibrillation
Doctor A. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Longitudinal assessment of ventricular arrhythmia burden before and after left ventricular assist device implantation: implications for risk stratification and postoperative management
Professor M. Kim (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Incidence and predictors of heart failure hospitalization after left ventricular assist device insertion
Doctor M. Bak (Seoul, KR)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in chronic heart failure - treatment 6

The Event

Event poster

Heart Failure 2024

13 May 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Thoracic fluid content as a marker of high intravenous diuretic requirements in patients hospitalized for heart failure decompensation
thumbnail
Congress Session
Late-Breaking Clinical Trials: advances in heart failure care
thumbnail
Congress Presentation
Prognostic importance of guideline-directed medical therapy after left ventricular assist devices: a 10-year single-centre experience

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources